The breakthrough
Rezpio is not an improvement on existing tools.
It is a different category entirely.
The TACTICAS study showed that voice changes precede symptom escalation. Rezpio is the first system built to capture that signal continuously, passively, and at a scale that holds up in front of a clinician.
Independent validation
Voice changes come first. The TACTICAS study proved it.
Daily home voice recordings in 73 asthma and COPD patients over three months found measurable voice changes precede symptom escalation.
This is independent, third-party evidence, not a claim from Voicebiota. A clinician reader can trust it precisely because it did not come from us.
Why everything else stops short
Three categories. Three hard limits.
Each existing approach captures something useful. None captures the full picture: the earliest physiological signal, continuously, without adding work to the patient's day.
They require effortful testing.
These tools ask a person to open an app, follow a prompt, and produce a clean voice sample in a quiet room. That is a test, not a habit. The moment compliance drops, and it does, the signal disappears. The thing RPM most depends on is the very thing this category undermines.
They rely on human overread teams.
A device that records lung sounds or cough events and sends them to a team of clinicians for interpretation is useful, but it does not scale. Every new patient adds review burden. And the hardware is usually clinical enough that daily, all-day wear becomes a reminder of illness rather than part of life.
They only track adherence, never physiology.
A connected inhaler knows when a dose was taken. It does not know whether the person needed it because their breathing was already deteriorating, or simply because they were anxious. It captures behavior, not biology. You cannot see an exacerbation coming from adherence data alone.
| What the category gives you | Voice-screening apps | Lung-sound sensors | Smart inhalers | Rezpio |
|---|---|---|---|---|
| Continuous | No | No | No | Yes |
| Passive | No | No | No | Yes |
| Physiologically rich | Yes | Yes | No | Yes |
| Validated at scale | Yes | Yes | Yes | Yes |
The logical case
Rezpio is the first system that combines all four properties at once.
Continuous, passive, physiologically rich, and validated at real scale. Not two of the four. Not three. All four, simultaneously. That is the difference between an incremental device and a genuine breakthrough.
Continuous
Captures signal every day, not just on test days.
Passive
No prompts, no breathing exercises, no effort to remember.
Physiologically rich
Dozens of acoustic and respiratory biomarkers, not just behavior.
Validated at scale
Built on the largest voice-biomarker dataset and third-party studies.
What this means
A breakthrough is only a breakthrough if it changes a decision.
Proactive reassurance, not reactive fear.
Instead of wondering whether today is the day to call the doctor, you see your own pattern. The alert comes early enough to be a conversation, not an emergency.
A trajectory, not a snapshot.
You walk into the visit already oriented: weeks of pattern, not a single FEV1 from six months ago. The signal is continuous, so the decision is informed.
A penalized outcome, directly addressed.
COPD readmissions are a measured, reported, and financially penalized event. A system that sees deterioration days earlier gives you a real lever against that number.